Multiple myeloma patients more vulnerable to 'financial toxicity' due to expensive, longer courses of treatments
Even patients with health insurance who have multiple myeloma may be vulnerable to "financial toxicity" – including those who make over $100,000 a year – because of the higher use of novel therapeutics and extended duration ...
Sep 30, 2015